Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06245213 · ClinicalTrials.gov registry record · Phase 2
A Study of ANAVEX3-71 in Adults With Schizophrenia
A Phase 2 study of Schizophrenia, sponsored by Anavex Life Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT06245213: Active Phase 2 study of Schizophrenia, sponsored by Anavex Life Sciences.
NCT06245213 is a Phase 2 study of Schizophrenia that is active but no longer recruiting, run by Anavex Life Sciences. The registered enrollment target is 71 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06245213, a Phase 2 study of Schizophrenia, is active but no longer recruiting, sponsored by Anavex Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
Primary Outcome
Pharmacokinetic blood measurements of ANAVEX3-71 and metabolite M8 at pre-dose, 0.5, 1, 2-, 3-, 4-, and 8-hours post-dose.
Conditions Studied
Interventions
- DRUG ANAVEX3-71 oral capsules
- DRUG Placebo oral capsules
Study Locations (1)
New Jersey
- CenExel Hassman Research Institute - Marlton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 2 |
What the registry record for NCT06245213 still lists
NCT06245213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which ANAVEX3-71 oral capsules is the first listed.
NCT06245213 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06245213 about?
NCT06245213 is a clinical study titled "A Study of ANAVEX3-71 in Adults With Schizophrenia". A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
What is the current status of trial NCT06245213?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2024-03-15. Estimated completion is 2025-06-30.
What conditions does trial NCT06245213 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT06245213?
The interventions under investigation include: ANAVEX3-71 oral capsules (DRUG), Placebo oral capsules (DRUG).
Who is sponsoring clinical trial NCT06245213?
This trial is sponsored by Anavex Life Sciences, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06245213 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06245213's enrollment target sits among peer trials
71 174th of 315 higher than 141 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia
RECRUITING · Phase 2
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
RECRUITING · Phase 2
-
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
RECRUITING · Phase 2
-
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia
RECRUITING · Phase 2
-
Study of ALTO-101 in Patients With Schizophrenia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI